Zhitong Finance App News, Sihuan Biotech (000518.SZ) announced that the company plans to acquire 80% of the shares of Jilin Changyuan Pharmaceutical Co., Ltd. (“Changyuan Pharmaceutical”) in cash at a transaction price of 160 million yuan. After the transaction is completed, Changyuan Pharmaceutical will become the company's holding subsidiary.

Changyuan Pharmaceutical is a pharmaceutical company focusing on drug R&D, production and sales. Currently, its main products include succinyl gelatin injections, brain thrombotic rehabilitation capsules, brain peptide capsules, Haidan capsules, hemorrhoid hemostatic pills, etc. Among them, the core product succinyl gelatin injection has a high market share and strong market competitiveness; in addition, brain thrombotic rehabilitation capsules, brain peptide capsules, and Haidan capsules are exclusive varieties; hemorrhoid hemostatic pills and seven patchouli tablets are exclusive dosage forms, which have certain market potential and space. This acquisition is in line with the company's current development strategy, and has obtained mature chemical formulations with competitive advantages in the market and a number of exclusive proprietary Chinese medicines, enriching the product matrix, and helping to achieve the company's “biological products+chemical preparations” business layout in the pharmaceutical field.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.